The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545) , is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third SERD clinical candidate from Genentech (after GDC-0810 and GDC-0927) and a number of oral SERDs have previously [...]
< 1 minute read
Dec. 16, 2021
Giredestrant: Oral Selective Estrogen Receptor Degrader (SERD) and Full Antagonist
giredestrant
selective ER degrader (SERD) + full antagonist oral (30 mg QD), Ph. III for ER+, HER2- BC from profiling >4k cmpds for desired MoA Journal of Medicinal Chemistry Genentech, San Francisco, US